Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Mestinon
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Ongoing clinical trials == === The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure === This small trial of Mestinon is currently being conducted by [[David Systrom]] in Boston, US, and involves patients with [[preload failure]], [[Myalgic encephalomyelitis|ME]], [[Chronic fatigue syndrome|CFS]], [[Fibromyalgia]] and [[Dyspnea]].<ref name="NCT03674541">{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT03674541 | title = The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure - NCT036745 | last = Systrom|first = David | authorlink=David Systrom | date = |website=Clinical trials|language=en|archive-url=|archive-date=|url-status=|access-date=2019-04-15}}</ref> This trial compares the effects of a single dose of 60mg of pyridostigmine bromide (Mestinon) with a placebo drug, and aims to measure the effects on [[post-exertional malaise]] and dyspnea.<ref name="NCT03674541" /> This trial is based on the theory that [[Small fiber peripheral neuropathy|small fiber neuropathy]] causes autonomic system dysfunction, resulting in breathlessness and post-exertional malaise.<ref name="NCT03674541" /> The trial is expected to finish in 2019. ===Droxidopa / Pyridostigmine in Orthostatic Hypotension=== A phase 2 randomized controlled trial involving 25 people taking both [[droxidopa]] and pyridostigmine. It is being conducted by Dr [[Phillip Low]] at the Mayo Clinic, in Rochester, [[:Category:Minnesota clinics|Minnesota]], US. Researchers state: :"The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while [[Droxidopa]] will replete the postganglionic neuron of [[norepinephrine]] (NE). This combination should result in enhanced orthostatic release of NE." <ref name="POTStrial2019">{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT01370512 | title = Droxidopa / Pyridostigmine in Orthostatic Hypotension - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2019-04-15}}</ref> ===A Study of Pyridostigmine in Postural Tachycardia Syndrome=== A three-day trial involving 50 people with [[Postural orthostatic tachycardia syndrome|POTS]] is being conducted by Dr [[Phillip Low]] at the Mayo Clinic, in Rochester, Minnesota, US. This is a blinded randomized controlled trial, comparing pyridostigmine with a placebo; researchers state they "expect pyridostigmine to improve tachycardia and stabilize blood pressure.<ref name="POTSTrial2020">{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT00409435 | title = A Study of Pyridostigmine in Postural Tachycardia Syndrome - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2019-04-15}}</ref>
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs